ADVI’s Lindsay Bealor Greenleaf spoke with Victor Reklaitis about the increased activity from lawmakers and lobbyists regarding drug prices MarketWatch
“There’s just such an increase in activity from lawmakers that it’s really not surprising to see an increase in lobbying activity as well,” Lindsay Bealor Greenleaf, a former registered lobbyist for drug manufacturers, told MarketWatch.
[el-text]
Written by Victor Reklaitis
***excerpt***
“There’s just such an increase in activity from lawmakers that it’s really not surprising to see an increase in lobbying activity as well,” Lindsay Bealor Greenleaf, a former registered lobbyist for drug manufacturers, told MarketWatch.
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.